Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,505.6 Cr
verified against source
Revenue YoY
7%
reported change
EBITDA
₹367.8 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Gland Pharma reported a solid Q1 FY26 with consolidated revenue of INR 1,506 crore (+7% YoY) and EBITDA of INR 368 crore (+39% YoY), driving margins to 24% (up 500bps YoY). PAT surged 50% YoY to INR 216 crore. The standout was Cenexi reaching EBITDA break-even (EUR 0.9 million) after several quarters of losses, aided by volume recovery and cost actions. Base business EBITDA margin improved to 35% (vs 29% YoY). U.S. revenue was flat due to Enoxaparin timing, but ex that grew 11%. Management reiterated mid-teen overall growth guidance, backed by upcoming launches of dalbavancin and CMS dry powder. GLP-1 cartridge capacity expansion to 140 million units by March 2026 is on track, with 20 million units expected to commercialize in FY27. Key risk: Cenexi's Q2 may dip due to summer shutdown, delaying margin ramp-up.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects Cenexi to deliver positive EBITDA in Q3 FY26, with Q2 being lower due to summer shutdown.
- Management reiterated guidance for mid-teen consolidated revenue growth for the full year, driven by U.S. launches and Cenexi recovery.
- The new 100 million cartridge line will be ready for commercialization by March 2026, adding to the existing 40 million capacity.
- Management expects to commercialize around 20 million pens/cartridges in FY27, primarily for RoW markets.
Risks flagged
- Management acknowledged that Q2 FY26 will see lower EBITDA at Cenexi due to a one-month thermal shutdown, potentially delaying the turnaround trajectory.
- An analyst raised concerns about potential U.S. tariffs under the Trump administration. Management noted no tariffs on pharma yet but acknowledged uncertainty and said they would pass on costs to partners.
- U.S. revenue was flat due to timing of Enoxaparin supplies, a large product. Management expects annual volumes to be intact but quarterly volatility may persist.
- Management indicated that the new 100 million cartridge line will not see significant utilization until FY29-30, as most markets open later. Near-term revenue contribution may be limited.
Key quotes
- Cenexi reached break-even this quarter. We are confident Synapse's performance will continue to improve.
- Q1 FY 2026 has marked the beginning of a meaningful turnaround. We remain firmly focused on our previous commitment: to deliver a positive EBITDA in Q3 FY 2026.
- We are estimating the EBITDA ramp-up happening in Q3 and then Q4 also. Q2 would be a little lower because of the one-month summer shutdown.
Research modules